Skip to main content

The latest news &
insights from ArteraAI

View company news, research articles, publications, and industry thought leadership currently making headlines in the cancer treatment space.

All Categories
Media Coverage
Publications
Videos
Insights
Press Releases

All Categories

Insights

Artera Product Webinar – August 2025

The ArteraAI Prostate Test is transforming the risk stratification landscape for treating prostate cancer. For lower-risk pat [...]

Media Coverage

FDA just signed off on AI predicting long-term cancer...

The ArteraAI prostate test uses artificial intelligence and biomarkers to predict if standard hormone therapy will be effecti [...]

Media Coverage

FDA Okays AI-Based Prostate Cancer Risk-Stratification Tool

The US FDA has granted De Novo marketing authorization for ArteraAI Prostate (Artera, Los Altos, California), a novel artific [...]

Media Coverage

Identifying Patients Who Will Benefit From Intensified Prostate Cancer...

Identifying men with high-risk, non-metastatic prostate cancer who will truly benefit from intensified treatment from therape [...]

Press Releases

U.S. FDA Grants Artera Breakthrough Device Designation for AI-Powered...

Artera, the developer of multimodal artificial intelligence (MMAI)-based prognostic and predictive cancer tests, announced to [...]

Media Coverage

AI Tool Accurately Predicts Prostate Cancer Outcomes Across Racial...

Mack Roach III, MD, professor of radiation oncology, medical oncology, and urology at the University of California, San Franc [...]

Media Coverage

Multimodal AI Shows No Evidence of Bias in Prostate...

The study evaluated the performance of a multimodal artificial intelligence model to close gaps in care and validate that AI [...]

Media Coverage

Artera Bullish on Prostate Cancer Test Following NYS Approval,...

NEW YORK – Startup firm Artera is continuing to make commercial progress with its artificial intelligence-based prostate canc [...]

Load More